Introduction
Post-translational modifications of histone amino terminal tails are important for chromatin dynamics and organisation. Methylation and acetylation of specific lysine residues, together with phosphorylation, polyADP-ribosylation and ubiquitylation modulate processes such as transcription, cell cycle progression, DNA damage responses, apoptosis and differentiation. 1, 2 Histone acetylation is associated with transcription. In contrast, constitutive heterochromatin, which is generally transcriptionally inert, contains low levels of histone acetylation and is characterised by trimethylated H3 lysine 9 and H4 lysine 20.
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Histone acetylation is governed by the opposing actions of histone acetyl transferases (HATs) and histone deacetylases (HDACs). Alterations in the structure or expression of HATs and HDACs are frequently reported in cancers and are linked to tumour development. Consequently, HDAC inhibitors (HDACIs) are undergoing trials as anticancer agents. [6] [7] [8] [9] HDACIs alone exert an antiproliferative effect and promote apoptosis in cancer cell-line models, but in addition HDACIs have been shown to sensitize cells to the cytotoxic effects of other anticancer drugs, particularly topoisomerase II poisons. [10] [11] [12] [13] [14] [15] [16] Topoisomerase poisons such as etoposide and epirubicin are of great clinical importance and are widely used in cancer therapy. 17, 18 Topoisomerase II is an essential enzyme that allows the passage of one DNA duplex through a second. During its reaction cycle the dimeric enzyme introduces an enzyme-bridged DNA doublestrand break (DSB) in one double helix through which a second duplex can be passed. At this stage each topoisomerase monomer is coupled to one free end of the first duplex through a 5'-phosphotyrosyl linkage. Topoisomerase poisons stabilise the enzyme-linked DSB, which is otherwise transient and rapidly re-ligated [19] [20] [21] . The resultant topoisomerase II-DNA covalent complexes account for the cytotoxic properties of the drugs and are presumed to be converted to "frank" DSBs by repair processes and/or result in a damage response following collisions with transcriptional or replication machinery. Mammals possess two topoisomerase II isoforms,  and , encoded by the TOP2A and TOP2B genes respectively 22, 23 . Although the isoforms have very similar enzymatic characteristics in vitro and share 70% amino acid identity, topoisomerase II and - have different though possibly overlapping roles in mammalian cells. Topoisomerase II is essential for cell viability and is required for chromosome decatenation after S-phase 20 , while top2null mice develop to term but die perinatally with neural developmental defects 24 . Recently, specific roles in transcription regulation and sperm chromatin remodelling have been uncovered for topoisomerase II [25] [26] [27] The topoisomerase II isoform is the major target for most clinically-relevant topoisomerase poisons including etoposide and epirubicin 12, 28, 29 although the - isoform appears to contribute more for some topoisomerase poisons including mitoxantrone, mAMSA and XK469. [28] [29] [30] Several mechanisms could explain the sensitization of cells to topoisomerase poisons by HDAC inhibitors 13, 15, 31 but notably, it was recently reported that this potentiation is mediated specifically through topoisomerase II. 12 This was shown for etoposide and epirubicin as well as mitoxantrone.
HDACIs cause chromatin decondensation, which may affect access of topoisomerase to DNA or access of topoisomerase poisons to the enzyme, 14, 32, 33 resulting in elevated DNA damage and cytotoxicity. HDACI treatment leads to global changes in histone acetylation levels, including hyperacetylation of heterochromatin and redistribution of the non-histone heterochromatin protein HP1. [34] [35] [36] [37] It follows that this may affect the distribution of topoisomerase II in the interphase nucleus.
Indeed, enzymatically active topoisomerase II is concentrated in heterochromatin in mid-late Sphase in HeLa cells and is delocalised by the HDACI TSA. 38 We have studied the nuclear distribution of topoisomerase II and show here that TSA leads to its redistribution in the nucleus and a change in the pattern of topoisomerase II-DNA complexes induced by etoposide in favour of a more euchromatic pattern. We suggest that altering the distribution of topoisomerase II in the nucleus and thus topoisomerase II-DNA adducts across the genome converts topoisomerase II into a more clinically useful target for topoisomerase poisons including etoposide. 
Materials and Methods

Results
A fraction of topoisomerase II is concentrated in heterochromatin
Exposure of cultured cells to HDAC inhibitors results in cell cycle arrest and apoptosis. Prolonged exposure to low doses leads to chromatin decondensation associated with hyperacetylation of histones H3 and H4. In mouse cells under these conditions, pericentromeric heterochromatin relocates from a largely perinucleolar to a more peripheral distribution and in mouse and human cells, HP1 proteins become dissociated from heterochromatic regions. 34, 36 In the light of this HDAC-mediated chromatin remodelling, and the role of topoisomerase II in sensitisation of cells to topoisomerase poisons by HDAC inhibitors, we hypothesised that HDAC inhibitors such as TSA or VPA may alter the subnuclear distribution of topoisomerase II. This, either directly or through increased accessibility of decondensed chromatin could lead to increased cytotoxicity associated with topoisomerase poisons.
Previous studies have reported differing subnuclear distributions for topoisomerase II.
Topoisomerase II has variously been reported to be concentrated in the nucleoli or at the periphery of heterochromatic regions in fixed cells, [43] [44] [45] and in live cells, 45 while others have not found the protein to be specifically nucleolar. 39, 46 The reasons for these differences are not clear, but probably reflect, at least in part, species differences and differences in specimen preparation. immunofluorescence remained unchanged by TSA (Fig. 4B) , consistent with previous observations. 34 When topoisomerase IIdissociated from heterochromatin it appeared in a fine speckled pattern throughout the nucleus and was occasionally excluded from heterochromatic regions ( Fig. 6 fourth and fifth rows).
Effect of HDAC inhibition on etoposide-induced topoisomerase-DNA complexes.
The topoisomerase II reaction mechanism allows the passage of one DNA duplex through another by transiently cleaving the first DNA helix to create an enzyme-bridge DNA gate through which the second duplex is transported. The break is subsequently ligated and the DNA structure restored. [19] [20] [21] During the cleavage reaction, a covalent enzyme-DNA intermediate is formed between a tyrosine residue of each topoisomerase II monomer and the 5'-phosphate group of the cleaved DNA. This enzyme-bridged double-strand break normally exists transiently, but the action of topoisomerase poisons such as etoposide is to stabilise these intermediates. Both topoisomerase II and  are targets for etoposide, and etoposide-induced topoisomerase II-DNA complexes can be visualised and quantified using a fluorescence microscopy based method (Trapped in AgaRose DNA ImmunoStaning, or TARDIS). 42 This method involves ionic detergent and salt extraction of agaroseembedded cells, resulting in removal of proteins not covalently coupled to the nuclear DNA, which is too bulky to elute from the agarose. Covalently coupled proteins are then detected by immunofluorescence. In a variation of this approach adherent cells are extracted in a similar fashion on glass coverslips under slightly less harsh conditions (DRT extraction) without agarose embedding. 38 We used this latter technique to examine the effect of TSA treatment on both the Notably, TSA treatment alone did not significantly affect the quantity of DRT extraction-resistant topoisomerase II (Fig S2) , nor did it affect the magnitude of etoposide induced histone H2AX phosphorylation, a marker for DNA double-strand breaks (not shown). However, we did find that it had an unexpected effect on the background pattern of H2AX. In control cells, H2AX is present in a faint speckled pattern in the nucleus, typically with one or a small number of bright foci, presumably originating from spontaneous DNA double-strand breaks (DSBs). However, in cells exposed to TSA for 5 days, H2AX was concentrated almost exclusively adjacent to large chromocentres (see Fig. 7 ).
These TSA-induced H2AX foci were not as intense as those induced by etoposide, which also form predominantly outside heterochromatin, 49 but contributed to an overall increase in background H2AX (Fig. 7A&B) . Notably, it has recently been demonstrated that HDAC inhibition slows replication and leads to replication-associated DNA damage and H2AX phosphorylation, 50 and we suspect that this is likely to be the cause of the TSA-induced peri-heterochromatic H2AXseen here.
Thus increased background h2AX phosphorylation and the redistribution of topoisomerase IIare likely to be independent effects of the TSA-mediated remodelling of heterochromatin.
The effect of HDACIs on the distribution of topoisomerase IIβ in human cells.
Since HDACIs have been shown to potentiate topoisomerase poisons in human cancer cell lines, we also examined the effect of TSA and valproic acid (VPA) on topoisomerase II distribution in the human lung cancer cell line A549. Topoisomerase II was distributed in a nucleoplasmic pattern, with some concentration in the perinucleolar regions of most cells (Fig. 8A) . The perinucleolar pattern was more pronounced when cells were permeabilised prior to fixation (Fig. 8B) . Nucleoli of human cells are typically surrounded by clusters of heterochromatin identified by late replication timing, histone methylation and the presence of HP1 proteins. 4, 49 In human cells, HP1 gives the most robust pericentromeric staining pattern of the three HP1 species. 36, 51 When we compared the distribution of HP1 to that of topoisomerase II, HP1 substantially coincided with the areas of brightest topoisomerase II signal (Fig. 8C) . When cells were treated with TSA or VPA, topoisomerase II adopted a more pan-nuclear distribution, as was observed following HDACI treatment of mouse cells (Fig. 3) . HP1 still presented a focal distribution under these conditions, as observed previously, 36 but these foci were no longer associated with bright topoisomerase II staining (Fig. 8C) . Thus, as in mouse C127I cells, topoisomerase II is partially concentrated in heterochromatic regions of the nucleus of A549 cells and is redistributed into a more uniform pattern upon HDACI treatment. We also investigated the distribution of topoisomerase II in two human lymphoblastoid cell lines K562
and Nalm-6. Topoisomerase II appeared nucleoplasmic in distribution in these cells, but after mild detergent extraction (CSK buffer) the remaining topoisomerase II was concentrated in the DAPIbright heterochromatic regions surrounding nucleoli or at the nucleolar periphery (Fig S3) , similar to the distribution in A549 cells.
Topoisomerase IIβ mediates the potentiating effect of HDACI
We investigated the ability of the HDACI valproic acid to potentiate the growth inhibitory/cytotoxic effects of topoisomerase poisons in A549 cells using a series of topoisomerase poisons with different selectivities for topoisomerase II and -, see Table 1 & Table S1 . The most robust potentiation was observed with mitoxantrone and mAMSA, while marginal potentiation was obtained for etoposide and no significant effect was seen for doxorubicin or epirubicin. Cells lacking topoisomerase II have previously been shown to be resistant to mitoxantrone and mAMSA, 28, 29 indicating a significant role for this isozyme in the cytotoxicity of these drugs, whereas the degree of resistance to etoposide or doxorubicin in topoisomerase II null cells was smaller. Similarly, we found the IC 50 for mitoxantrone in growth inhibition assays is five times higher in topoisomerase IInull Nalm-6 cells than in their wild type counterparts while the ratio is only 2.8 for etoposide (data not shown). Thus, these data support previous work 12 identifying a functional interaction between topoisomerase II and HDAC inhibitors such as VPA in the synergistic action of histone deacetylase inhibitors with topoisomerase poisons.
What causes topoisomerase IIβ to be retained in heterochromatin?
The very similar subnuclear localization of topoisomerase II and HP1 and their parallel dispersal from heterochromatin following TSA treatment suggests that the two proteins might interact in a protein-protein complex. Another piece of evidence that suggests this is the very similar phenotype of mice null for TOP2b and CBX1, the genes encoding topoisomerase II and HP1 respectively. Both
TOP2b and CBX1 null mice develop apparently normally in utero, but die perinatally from respiratory failure due to failure to innervate the diaphragm. 24, 52 We carried out a co-immunoprecipitation experiment to determine whether HP1 and topoisomerase II exist in a stable protein complex. is limited to constitutive heterochromatin. As was observed in mouse cells, topoisomerase II was redistributed following TSA or VPA treatment (Fig. 8) . TSA also altered the distribution of etoposideinduced topoisomerase II-DNA complexes. In non-TSA treated C127I cells, adducts were concentrated in heterochromatic regions, reflecting the distribution of the enzyme in these cells, while after TSA treatment, adducts were distributed more evenly throughout the nucleus.
We have not addressed the HDAC specificity of the observed topoisomerase II redistribution, but we note that HDAC2 was found to be the predominant target in MCF7 cells for HDACIs with regards to chromatin decondensation, downregulation of HP1 and other chromatin proteins and potentiation of epirubicin cytotoxicity. 33 We have employed TSA and VPA in the work reported here. Both inhibit HDAC2, although VPA but not TSA selectively induces proteasomal degradation of HDAC2. 53 In addition, topoisomerase II and II physically interact with HDAC1 and HDAC2 and topoisomerase II is associated with HDAC1 in the NuRD complex. 16, 54 Previous descriptions of the intranuclear distribution of topoisomerase II have varied in the literature. 39, [43] [44] [45] [46] This may reflect the dynamic nature of topoisomerase IITopoisomerase IIis recruited to the promoters of certain genes during transcriptional activation 25, 26 and it is possible that the HDACI-induced redistribution of topoisomerase II reported here reflects the normal dynamic behaviour of the protein during the execution of transcriptional programs, though this possibility remains to be explored. We have consistently observed topoisomerase II to be concentrated in chromocentres in untreated fixed mouse cells ( Fig. 1-3 & S1) . Notably, this distribution is mirrored in the pattern of topoisomerase II-DNA adducts formed in living cells by etoposide (Fig. 6) , arguing against the observed pattern being an artefact of fixation. Table S1 ). Where potentiation is scored as "YES", IC50 values obtained with VPA were significantly lower than that obtained with topoisomerase poison alone (p<0.05 one tailed paired t-test). Topoisomerase II preference pertains to evidence for the relative involvement of topoisomerase II or - in mediating the cytotoxic effects in cell line systems (Errington et 
